Monoclonal antibodies have 'good track record' in treating migraines, expert says
DENVER — Monoclonal antibodies have shown promise as an emerging treatment for migraine, Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, said at the American Headache Society annual scientific meeting. “What we've learned from looking back at clinical trial data is that the monoclonal antibodies have very low numbers needed to treat, and very high numbers needed to harm —